Trial Profile
A Phase 2/3, Multicenter, Open-label Clinical Study to Assess the Safety and Efficacy of BAY86-6150 in Subjects With Hemophilia A or B With Inhibitors, Composed of 2 Parts (A ' B). Part A: Sequential Cohorts of Four Dose Levels of the Modified rFVIIa BAY86-6150 Assessed in a Non-controlled Dose Response Design in Acutely Bleeding Subjects and for PK/ PD in an Intra-individual Crossover Design Compared With One Fixed Dose of Eptacog Alfa in Non-bleeding Subjects. Part B: Confirmatory Study to Further Investigate the Efficacy and Safety of BAY86-6150
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs BAY 866150 (Primary) ; Eptacog alfa
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions; Therapeutic Use
- Acronyms TRUST
- Sponsors Bayer
- 10 Dec 2022 This trial has been completed in Denmark according to European Clinical Trials Database record.
- 04 Oct 2014 New source identified and integrated (European Clinical Trials database record:EudraCT2011-000323-33).
- 27 Mar 2014 New trial record